Previous close | 1.5000 |
Open | 1.5800 |
Bid | 1.5400 x 1000 |
Ask | 1.6000 x 36900 |
Day's range | 1.5000 - 1.5800 |
52-week range | 1.4610 - 4.3700 |
Volume | |
Avg. volume | 112,203 |
Market cap | 25.177M |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.2000 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.50 |
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the peer-reviewed journal Nature Medicine that supports the clearance of senescent cells in the retina as a therapeutic approach that can lead to long-term improvements in vision in patients with diabetic macular edema (DME). Sustained hyperglycemia fr
In this article, we are going to discuss the 10 Supplements for Longevity and Antiaging: Expert Recommendations. You can skip our detailed analysis and go directly to 5 Supplements for Longevity and Antiaging: Expert Recommendations. The anti-aging and longevity market is undergoing a fascinating transformation, driven by personalized approaches, cutting-edge science, and a growing emphasis on evidence-based […]
Topline 16-week data expected in the fourth quarter of 2024SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema